Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors

Patent metadata

Field	Value
Publication number	US-12589165-B2
Application number	US-201816604790-A
Country	US
Kind code	B2
Filing date	Apr 11, 2018
Priority date	Apr 12, 2017
Publication date	Mar 31, 2026
Grant date	Mar 31, 2026

Abstract

Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.

First claim

What is claimed is:

1 . A method for treating a bladder tumor, comprising:
(a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection; (b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from anti-PD-1 antibodies, anti-CTLA-4 antibodies, and anti-LAG3 antibodies, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection; and (c) activating the photosensitive molecules using an infrared laser, a near-infrared laser, or an ultraviolet laser.

2 . The method of claim 1 , wherein the human papillomavirus capsid proteins comprise papillomavirus L1 capsid proteins.

3 . The method of claim 2 , wherein the human papillomavirus capsid proteins comprise a combination of human papillomavirus L1 capsid proteins and human papillomavirus L2 capsid proteins.

4 . The method of claim 1 , wherein the virus-like particle conjugate comprises 10 to 1000 photosensitive molecules.

5 . The method of claim 4 , wherein the virus-like particle conjugate comprises about 200 photosensitive molecules.

6 . The method of claim 1 , wherein the photosensitive molecules comprise an infrared (IR) dye.

7 . The method of claim 1 , wherein the photosensitive molecules comprise a near infrared (NIR) dye.

8 . The method of claim 1 , wherein the photosensitive molecules comprise a phthalocyanine dye.

9 . The method of claim 1 , wherein the immune checkpoint inhibitor is pembrolizumab.

10 . The method of claim 1 , wherein the immune checkpoint inhibitor is nivolumab.

11 . The method of claim 1 , wherein the immune checkpoint inhibitor is ipilimumab.

12 . The method of claim 1 , wherein the primary bladder tumor is cancerous.

13 . The method of claim 1 , wherein the primary bladder tumor is a melanoma, carcinoma, sarcoma or lymphoma.

14 . The method of claim 1 , wherein the composition comprising an immune checkpoint inhibitor is administered via intravenous injection.

15 . A method for treating a bladder tumor, comprising:
(a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive infrared dye molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection; (b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from pembrolizumab, nivolumab, and ipilimumab, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection; and (c) activating the photosensitive infrared dye molecules using an infrared laser.

16 . The method of claim 15 , wherein the human papillomavirus capsid proteins comprise a combination of human papillomavirus L1 capsid proteins and human papillomavirus L2 capsid proteins.

17 . The method of claim 15 , wherein the virus-like particle conjugate comprises 10 to 1000 photosensitive molecules.

18 . The method of claim 17 , wherein the virus-like particle conjugate comprises about 200 photosensitive molecules.

19 . The method of claim 15 , wherein the primary bladder tumor is a melanoma, carcinoma, sarcoma or lymphoma.

20 . The method of claim 15 , wherein the composition comprising an immune checkpoint inhibitor is administered via intravenous injection.

Assignees

• Aura Biosciences Inc
• Us Health

Inventors

• De Los Pinos Elisabet
• Schiller John Todd
• Kines Rhonda C

Classifications

• C12N2710/20071

  Demonstrated in vivo effect · CPC title

• C12N2710/20042

  virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title

• C12N2710/20023

  Virus like particles [VLP] · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title